KYS

KYS Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation multi-specific antibodies for oncology and autoimmune disorders. The company leverages its proprietary platform to engineer biologics that target complex disease mechanisms, with a primary focus on B-cell-mediated pathologies. Its lead candidate, KYS-0502, is a bispecific antibody targeting CD38 and CD3, currently being evaluated for the treatment of multiple myeloma and systemic lupus erythematosus. KYS Therapeutics maintains a global presence with operations in both South Korea and the United States, aiming to provide transformative therapies for patients with high unmet medical needs.